SH2B2: A Protein Targeted for Drug Research (G10603)

Target Name: SH2B2

NCBI ID: G10603

SH2B2

SH2B2: A Protein Targeted for Drug Research

SH2B2 (SH2B2_HUMAN), also known as human SH2B2, is a protein that is expressed in various tissues throughout the body. It is a member of the SH2 family of proteins, which are known for their role in intracellular signaling. SH2B2 has been identified as a potential drug target and is the focus of research at the laboratory of Dr. Xin Xu at the University of California, San Diego.

The SH2 family of proteins is characterized by the presence of a nucleotide-binding oligomerization domain (NBD), which is a key structural element that allows the proteins to interact with nucleotides. The NBD is responsible for the formation of a nucleotide-binding complex, which can then interact with various proteins to regulate cellular processes such as cell growth, differentiation, and inflammation.

SH2B2 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, liver, and kidney. It is primarily localized to the cytoplasm and is highly homologous to the nucleus. SH2B2 plays a key role in intracellular signaling by regulating the activities of various cellular proteins.

One of the key functions of SH2B2 is its role in the regulation of cell adhesion. SH2B2 has been shown to interact with the protein Focal Adhesion Assay (FAA), which is a protein that is involved in cell-cell adhesion. By interacting with FAA , SH2B2 has been shown to regulate the formation of tight junctions, which are a type of cell-cell adhesion that is critical for maintaining tissue structure and function.

Another function of SH2B2 is its role in the regulation of cell signaling pathways. SH2B2 has been shown to interact with a variety of proteins involved in cell signaling, including the protein Pyruvate Kinase (PK). PK is a critical enzyme involved in the regulation of cellular energy metabolism and is a potential drug target for the treatment of various diseases, including cancer.

In addition to its role in cell signaling, SH2B2 is also a potential biomarker for a variety of diseases. For example, SH2B2 has been shown to be elevated in the blood of patients with various diseases, including cancer, heart disease, and neurodegenerative diseases. Additionally, SH2B2 has been shown to be expressed in various tissues and cells that are affected by certain diseases, such as neurodegenerative diseases.

Overall, SH2B2 is a protein that has important roles in intracellular signaling and cell adhesion. Its potential as a drug target and biomarker make it an attractive target for future research. Further studies are needed to fully understand the functions of SH2B2 and its potential as a drug.

Protein Name: SH2B Adaptor Protein 2

Functions: Adapter protein for several members of the tyrosine kinase receptor family. Involved in multiple signaling pathways. May be involved in coupling from immunoreceptor to Ras signaling. Acts as a negative regulator of cytokine signaling in collaboration with CBL. Binds to EPOR and suppresses EPO-induced STAT5 activation, possibly through a masking effect on STAT5 docking sites in EPOR. Suppresses PDGF-induced mitogenesis. May induce cytoskeletal reorganization via interaction with VAV3

The "SH2B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH2B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets